Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/3G6 stock hub

FRA/3G6 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/3G6is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

901M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/3G6FRA/3G6

—

Loading chart…

In the news

Latest news · FRA/3G6

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-15.6

P25 n/aP50 n/aP75 n/a

ROIC-7.1

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/3G6 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

178

Groups with data

Currency

JPY

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Japan
Country code	DE
Employees	990
Employees Change	24%
Employees Change Percent	2.85
Enterprise value	EUR 823.9M
Exchange	Frankfurt Stock Exchange
Financial currency	JPY
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 901M
Price	EUR 15.8
Price currency	EUR
Rev Per Employee	147,272.33x
Sic	2836
Symbol	fra/3G6
Website	https://www.gnipharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.56%
EV Earnings	-35.74x
EV/FCF	-55.31x
EV/Sales	5.66x
FCF yield	-1.65%
P/B ratio	3.2x
P/S ratio	6.18x
PE Ratio10 Y	254.79x
PE Ratio3 Y	218.55x
PE Ratio5 Y	146.65x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-9.33%
EBITDA Margin	-5.09%
Gross margin	74.49%
Gross Profit	EUR 108.6M
Gross Profit Growth	10.85%
Gross Profit Growth Q	28.88%
Gross Profit Growth3 Y	10.68%
Gross Profit Growth5 Y	19.43%
Net Income	EUR -23.1M
Pretax Margin	-17.27%
Profit Margin	-15.81%
Profit Per Employee	EUR -23,287
ROA	-2.01
Roa5y	1.99
ROCE	-3.37
ROE	-15.62
Roe5y	2.86
ROIC	-7.07
Roic5y	0.28

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	7.05%
Cagr15y	22.1%
Cagr1y	13.68%
Cagr3y	33.1%
Cagr5y	1.32%
Revenue Growth	13.68x
Revenue Growth Q	16.58x
Revenue Growth3 Y	15.5x
Revenue Growth5 Y	22.39x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.34
Assets	EUR 455.2M
Cash	EUR 114.6M
Current Assets	EUR 220.5M
Current Liabilities	EUR 51.9M
Debt	EUR 29.1M
Debt Equity	EUR 0.1
Debt FCF	EUR -1.96
Equity	EUR 281.6M
Interest Coverage	-1.44
Liabilities	EUR 173.6M
Long Term Assets	EUR 234.7M
Long Term Liabilities	EUR 121.6M
Net Cash	EUR 85.5M
Net Cash By Market Cap	EUR 9.49
Net Cash Growth	440.76%
Net Debt Equity	EUR -0.3
Tangible Book Value	EUR 115.8M
Tangible Book Value Per Share	EUR 2.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.25
Inventory Turnover	2.18
Net Working Capital	EUR 67.3M
Quick ratio	3.04
Working Capital	EUR 169.2M
Working Capital Turnover	EUR 0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.05%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	97.58%
1Y total return	13.67%
200-day SMA	14.68
3Y total return	135.82%
50-day SMA	16.76
50-day SMA vs 200-day SMA	50over200
5Y total return	6.76%
All Time High	31.6
All Time High Change	-50%
All Time High Date	2020-10-05
All Time Low	0.07
All Time Low Change	21,455.25%
All Time Low Date	2009-02-26
ATR	0.46
Ch YTD	23.44
High	15.8
High52	26
High52 Date	2025-05-30
High52ch	-39.23%
Low	15.8
Low52	11.9
Low52 Date	2025-12-03
Low52ch	32.77%
Ma50ch	-5.72%
Price vs 200-day SMA	7.61%
RSI	44.55
RSI Monthly	50.55
RSI Weekly	51.39
Sharpe ratio	0.43x
Sortino ratio	0.81
Total Return	-1.05%
Tr YTD	23.44
Tr15y	1,900%
Tr1m	-4.24%
Tr1w	-1.25%
Tr3m	21.54%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -13.6M
Operating margin	-9.33

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	54,056,390%
Net Borrowing	-11,875,199.6
Shares Insiders	3.04%
Shares Institutions	10.97%
Shares Qo Q	3.96%
Shares Yo Y	1.05%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -14.9M
Average Volume	0x
Bv Per Share	4.91
CAPEX	EUR -1.8M
Ch10y	97.57
Ch15y	1,900
Ch1m	-4.24
Ch1w	-1.25
Ch1y	13.67
Ch3m	21.54
Ch3y	135.8
Ch5y	6.76
Ch6m	15.33
Change	-2.47%
Change From Open	0
Close	16.2
Days Gap	-2.47
Depreciation Amortization	6,154,103
Earnings Date	2026-05-15
EBIT	EUR -13.6M
EBITDA	EUR -7.4M
EPS	EUR -0.44
F Score	2
FCF	EUR -14.9M
FCF EV Yield	-1.81x
Financing CF	74,627,234
Fiscal Year End	December
Founded	2,001
Goodwill	90,108,625.2
Income Tax	EUR 13.7M
Investing CF	-2,911,646
Is Primary Listing	0
Last Earnings Date	2026-02-13
Last Report Date	2025-12-31
Last Split Date	2019-09-02
Last Split Type	Forward
Ma150	14.49
Ma150ch	9.07%
Ma20	16.64
Ma20ch	-5.02%
Net CF	59,677,886
Next Earnings Date	2026-05-15
Open	15.8
Ppne	40,599,759.6
Price Date	2026-05-08
Ptbv Ratio	7.78
Relative Volume	20x
Revenue	145,799,604x
Tax By Revenue	9.37x
Tr6m	15.33%
Volume	0
Z Score	3.49

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/3G6 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/3G6 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/3G6?

Insider, institutional, and short-interest positioning.

Institutional ownership

+11.0%

Share of float held by funds and institutions

Insider ownership

+3.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+1.0%

Negative means the company is buying back shares.

Technical

FRA/3G6 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.6

Neutral momentum band

Price vs 200-day MA

+7.6%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.43

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/3G6

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/3G6 stock rating?

fra/3G6 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/3G6 analysis?

The full report lives at /stocks/fra/3G6/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/3G6?

The latest report frames fra/3G6 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/3G6 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.